SYCE3 siRNA (h): sc-75512



The Power to Question

BACKGROUND

Chromosome 22 contains over 500 genes and about 49 million bases. Being the second smallest human chromosome, 22 contains a surprising variety of interesting genes. Phelan-McDermid syndrome, neurofibromatosis type 2 and autism are associated with chromosome 22. A schizophrenia susceptibility locus has been identified on chromosome 22 and studies show that 22q11 deletion symptoms include a high incidence of schizophrenia. Translocations between chromosomes 9 and 22 may lead to the formation of the Philadelphia chromosome and the subsequent production of the novel fusion protein, Bcr-Abl, a potent cell proliferation activator found in several types of leukemia. The C22orf41 gene product has been provisionally designated in human L0C644186 pending further characterization. The rodent homologs have been designated 1700007E06Rik and RGD1563996 in mouse and rat respectively.

REFERENCES

- 1. Gilbert, F. 1998. Disease genes and chromosomes: disease maps of the human genome. Chromosome 22. Genet. Test. 2: 89-97.
- Schwab, S.G. and Wildenauer, D.B. 1999. Chromosome 22 workshop report. Am. J. Med. Genet. 88: 276-278.
- Tsilchorozidou, T., et al. 2004. Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2. J. Med. Genet. 41: 529-534.
- 4. Arinami, T. 2006. Analyses of the associations between the genes of 22q11 deletion syndrome and schizophrenia. J. Hum. Genet. 51: 1037-1045.
- Paylor, R., et al. 2006. TBX1 haploinsufficiency is linked to behavioral disorders in mice and humans: implications for 22q11 deletion syndrome. Proc. Natl. Acad. Sci. USA 103: 7729-7734.
- Zheng, X., et al. 2006. Bcr and its mutants, the reciprocal t(9;22)-associated Abl/Bcr fusion proteins, differentially regulate the cytoskeleton and cell motility. BMC Cancer 6: 262.
- Ahronowitz, I., et al. 2007. Mutational spectrum of the NF2 gene: a metaanalysis of 12 years of research and diagnostic laboratory findings. Hum. Mutat. 28: 1-12.
- 8. Hay, B.N. 2007. Deletion 22q11: spectrum of associated disorders. Semin. Pediatr. Neurol. 14: 136-139.
- 9. Tsilchorozidou, T., et al. 2004. Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2. J. Med. Genet. 41: 529-534.

CHROMOSOMAL LOCATION

Genetic locus: SYCE3 (human) mapping to 22g13.33.

PRODUCT

SYCE3 siRNA (h) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see SYCE3 shRNA Plasmid (h): sc-75512-SH and SYCE3 shRNA (h) Lentiviral Particles: sc-75512-V as alternate gene silencing products.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNAse-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

SYCE3 siRNA (h) is recommended for the inhibition of SYCE3 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com